Q2 revenue up 36%, PAT up 82%; FY27 EBITDA margin target 22-23%

Management guided margin improvementInvestor Communications View source PDF Explain this filing

BALAMINES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.8%Reaction day

₹1756.10

prior close

₹1780.90

announcement price

In-mkt

timing

Nifty Microcap 250market+2.2%-1.4% vs market

Specialty Chemicals peers, median of 98sector+1.3%-0.5% vs sector

On the reaction day the stock moved 1.4 pts less than Nifty Microcap 250 and 0.5 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.1

15m

-0.3

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.8+2.2-1.4+1.3-0.5

Next day

+1.6+3.3-1.7+2.2-0.6

+0.4pendingpending+1.0-0.6

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 98Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Consolidated Q2 FY27 revenue rose 36% year on year to ₹472 crore, EBITDA increased 58% to ₹106 crore, and PAT rose 82% to ₹67 crore. H1 revenue reached ₹933 crore and PAT ₹146 crore. Volumes were held back by raw material availability and supply delays. Management targets a 22-23% FY27 EBITDA margin. DME and expanded ACN are operational, while NMM and BSCL projects are due in FY27.

Likely market impact

Strong profit growth and new capacity milestones are positive, but supply constraints and commissioning risks may limit near-term gains.